Professor Luo Jianhua's team uses CRISPR to transform oncogenes into anti-oncogenes

Recently, the team of Professor Luo Jianhua from the University of Pittsburgh used CRISPR technology to effectively target the fusion of carcinogenic fusion genes, significantly improving the survival rate of invasive liver cancer and prostate cancer mice. This achievement was published in Nature, a subsidiary of Nature Biotechnology.

"This is the first time that gene editing technology has been used to specifically target carcinogenic fusion genes," said Professor Luo Jianhua, author of the article. "This is really exciting because it lays the foundation for a new approach that could become a cure for cancer."

A fusion gene refers to the fact that two originally isolated genes are linked together due to a mutation. Thus, a new gene produced by merging all or part of the original two genes may express a carcinogenic abnormal protein.

罗建华教授团队采用CRISPR将致癌基因改造为抗癌基因

â–²How to generate fusion genes (Source: Wikipedia)

Scientists use CRISPR-Cas9 gene editing technology to target unique DNA sequences formed by gene fusion, namely TMEM135–CCDC67 and MAN2A1–FER oncogenic fusion genes. They used an adenoviral vector to deliver the Cas9D10A enzyme and the guide RNA to target the DNA sequence around the fusion point and introduce herpes simplex virus type 1 thymidine kinase (HSV1-tk) with homologous fragments around the breakpoint. The gene is inserted in order to reconnect the two ends of the breakpoint. Thus, only cancer cells carrying the target fusion gene were specifically inserted into the HSV1-tk gene and were observed by the EGFP fluorescent label added to the HSV1-tk gene. When the current drug molecule ganciclovir (ganciclovir) is added, it is phosphorylated by the HSV1-tk enzyme to produce cytotoxic products, which cause apoptosis of cancer cells. It can be seen that if this new treatment idea is successfully applied to the clinic, it will significantly reduce the side effects of cancer therapy.

罗建华教授团队采用CRISPR将致癌基因改造为抗癌基因

▲The idea of ​​gene editing carcinogenic fusion gene (Source: "Nature Biotechnology")

Modified Soybean Pholipid

Modified soybean phospholipid refers to a type of phospholipid that has been altered or processed in some way to improve its functionality or suitability for various applications. This can include changes to the chemical composition, molecular structure, or physical properties of the phospholipid.

Modified Soybean Pholipid,Modified Soybean Lecithin Oil,Modified Soy Lecithin Oil,Modified Soy Lecithin

Jiangsu Chenwei Biology and Technology Co. LTD , https://www.cwsoybean.com

Posted on